Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression

Pancreas

Volumn 27, Issue 2, 2003, Pages 174-179

  Li, Xinquan ^a   Ding, Xianzhong ^a   Adrian, Thomas E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Arsenic trioxide; Cell cycle; Pancreatic cancer

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; CASPASE 7; CASPASE 9; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P21;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL POPULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; ARSENICALS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CASPASE 3; CASPASE 7; CASPASE 9; CASPASES; CCAAT-ENHANCER-BINDING PROTEINS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; ENZYME ACTIVATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM PROTEINS; OXIDES; PANCREATIC NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TRANSCRIPTION FACTOR CHOP; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0041592591     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200308000-00011     Document Type: Article

References (41)

1. Antman KH, Introduction. The history of arsenic trioxide in cancer therapy. Oncologist. 2001;6:1-2.
2. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist. 2001;6:3-10.
3. Forlner CE, Scott TFM. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA. 1931;97:3-5.
4. Sun HD, Ma L, Hu XC, et al. Ai-Lin 1 treated 32 cases of acute promyelocytic leukemia. Chin. J Integrat Chin West Med. 1992;12:170-172.
5. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3345-3360.
6. Ni J, Chen G, Shen Z, et al. Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia. Chin Med J (Engl). 1998;111: 1107-1110.
7. Chen Z, Chen GQ, Shen ZX, et al. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Semin Hematol. 2001;38: 26-36.
8. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339: 1341-1348.
9. Lin CP, Huang MJ, Chang IY, et al. Successful treatment of all-trans retinoic acid resistant and chemotherapy naive acute promyelocytic patients with arsenic trioxide-two case reports. Leuk Lymphoma. 2000;38:191-194.
10. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute myeloid leukaemia. J Clin Oncol. 2001;19:3852-3860.
11. Kwong YL, Au WY, Chim CS, et al. Arsenic trioxide- and idarubicin-induce remissions in relapsed acute promyelocytic leukemia: Clinicopathological and molecular features of a pilot study. Am J Hematol. 2001;66:274-279.
12. Wang ZG, Rivi R, Delva L, et al. Arsenic trioxide and melarsorol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RAR alpha independent manner. Blood. 1998;92:1497-1504.
13. Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase 3 activation in arsenic-induced apoptosis. J Cell Physiol. 1998;177:324-333.
14. Ozaki M, Deshpande SS, Angkeow P, et al. Rac 1 regulates stress-induced redox-dependent heat shock factor activation. J Biol. Chem. 2000;275:35377-35383.
15. Hei TK, Liu SX, Waldern C. Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc Natl Acad Sci U S A. 1998;95:8103-8107.
16. Liu SX, Athar M, Lippai I, et al. Induction of oxyradicals by arsenic: implication for mechanism of genotoxicity. Proc Natl Acad Sci U S A. 2000;98:1643-1648.
17. Lew YS, Brown SL, Griffin RJ, et al. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res. 1999;59:6033-6037.
18. Huang C, Ma WY, Li JX, et al. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res. 1999; 59:3035-3058.
19. Warrell RP, De The H, Wang ZY, et al. Acute promyelocytic leukemia. N Engl J Med. 1993;329:177-189.
20. Muller S, Matunis MJ, Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 1998; 17:61-70.
21. Li X, Ding X, Adrian TE. Arsenic trioxide inhibits proliferation and induces apoptosis in pancreatic cancer cells. Anticancer Res. 2002;22:2205-2213.
22. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia: As203 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR/PML protein. Blood. 1996;88:1052-1061.
23. Xiao D, Sun G, Wu W. Protein tyrosine kinase (PTK) activities during the induction of apoptos is by arsenic trioxide (As203). Zhonghua Xue Ye Xue Za Zhi. 1998;19:234-236.
24. Perkins C, Kim CN, Fang G, et al. Arsenic induces apoptosis of multidrug-resistant human myoloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x (L). Blood. 2000;95:1014-1022.
25. Cai X, Shen YL, Zhu Q, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia. 2000;14:262-270.
26. Seol JG, Park WH, Kim ES, et al. Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. Biochem Biophys Res Comm. 1996;265: 400-404.
27. Park WH, Seol JG, Kim ES, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000;60: 3065-3071.
28. Chai J, Shiozaki E, Srinivasula SM, et al. Structure basis of caspase-7 inhibition by XIAP. Cell. 2001;104:769-780.
29. Thornberry NA, Lazebnik Y. Caspase: enemies within. Science. 1998;281:1312-1316.
30. Akao Y, Nakagama Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase-3 in vitro. FEBS Lett. 1999;455:59-62.
31. Jiang XH, Wong BCY, Yuen ST, et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer. 2001;91:173-179.
32. Mancini M, Nicholson DW, Roy S, et al. The caspase-3 precursor has a cytosolic and mitochondrial distribution: implications for apoptotic signaling. J Cell Biol. 1998;140:1485-1495.
33. Kothakota S, Azuma T, Reinhard C, et al. Caspase-3 generated fragment of gelsolin: effector of morphological change in apoptosis. Science. 1997;278:294-298.
34. Sherr CJ, G1 Phase Progression. Cycling On Cue. Cell. 1994;79:551-555.
35. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Canc Res. 1995;55:5187-5190.
36. Takahashi S, Saito S, Ohtani N, et al. Involvement of the Oct-1 regulator element of the gadd 45 promoter in the p53-independent response to ultraviolet irradiation. Cancer Res. 2001;61:1187-1195.
37. Patton GW, Paciga JE, Shelley SA. NR8383 alveolar macrophage toxic growth arrest by hydrogen peroxide is associated with induction of growth-arrest and DNA damage-inducible genes GADD 45 and GADD153. Toxicol Appl Pharmacol. 1997;147:126-134.
38. Ou YC, Thompson SA, Kirchner SC, et al. Induction of growth arrest and DNA damage-inducible genes gagg 45 and gadd153 in primary rodent embryonic cells following exposure to methymercury. Toxicol Appl Pharmacol. 1997;147: 31-38.q
39. Carrier F, Zhan Q, Alamo I, et al. Evidence for distinct kinase-mediated pathways in GADD gene responses. Biochem Pharmacol. 1998;55:853-861.
40. Zhan Q, Fan S, Smith ML, et al. Abrogation of p53 function affects GADD gene responses to DNA base-damaging agents and starvation. DNA Cell Biol. 1996; 15:805-815.
41. Iwama K, Nakajo S, Aiuchi T, et al. Apoptosis induced by arsenic trioxide in leukemia U937 cells is dependent on activation of p38, inactivation of ERK and the Ca2+-dependent production of superoxide. Cancer Res. 2001;92:518-526.